

AM I ELIGIBLE?

If you're living with bipolar depression, you may be eligible for the ALTO-100-211 study.

The ALTO-100-211 study is looking for adults who:*

- Are 18-70 years old
- Have an existing diagnosis of bipolar disorder with depression (BD-I or BD-II) and are currently depressed
- Are willing to comply with all study assessments and procedures
- Must not be pregnant or breastfeeding

*Additional eligibility criteria apply

If you meet these criteria, the ALTO-100-211 study may be of interest to you.



**ARE YOU EXPERIENCING
SYMPTOMS OF
BIPOLAR DEPRESSION?**

To learn more and see if you may be eligible, visit: [insert study website URL, ClinicalTrials.gov Identifier/ URL, QR Code] or <https://clinicaltrials.gov/study/NCT06656416>.

Alto Neuroscience and its logo are registered trademarks of Alto Neuroscience Inc. © 2025 Alto Neuroscience Inc. All rights reserved.
01/2025 Version 1.0 07Jan2025



WHAT IS BIPOLAR DEPRESSION?

Bipolar depression is diagnosed based on a history of mania or hypomania and the presence of a current major depressive episode. Symptoms can impair your functioning at work or school, your social and personal relationships, and other important aspects of your life.

ABOUT THIS STUDY

This study is intended to assess the safety and effectiveness of ALTO-100 (an investigational medication) in adults with bipolar-I or bipolar-II depression.

The study will last approximately 3 to 4 months, consisting of a screening period (about 6 weeks), followed by a 6-week double-blind treatment period where you may receive ALTO-100 or placebo. If you complete the double-blind treatment period, you will be given the option to enter a 7-week open-label period where you are guaranteed to receive ALTO 100. Eligible participants will receive study-related care and evaluations at no cost. Compensation for your time and travel may be available.

Importantly, as a study participant you will remain under the care of your current provider while also working with a team of physicians and study staff who will monitor your overall health while participating in the trial. You will work with a current provider to ensure information is shared with them if that is their preference and you will continue under the care of your current provider after completing the trial.



WHY PARTICIPATE?

Clinical research participation is an important part of developing new treatments. To assess the safety and effectiveness of new drugs, research requires people like you to volunteer and help.

Participation in a clinical research study is completely voluntary, and you may withdraw from a clinical research study at any time for any reason. There is always some risk associated with participation. If you have questions about this study or would like more information contact your local study center.



THE FACTS ABOUT BIPOLAR DEPRESSION

Bipolar disorder with depression (BD-D) affects approximately 1% of the adult population in any given year¹.

Depression overall is the #1 contributor to disability worldwide².

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication [published correction appears in Arch Gen Psychiatry. 2007 Sep;64(9):1039]. Arch Gen Psychiatry. 2007;64(5):543-552

2. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx). <http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b> (Accessed 1 May 2021).

